Scientists at St. Jude Children's Research Hospital and Dana-Farber Cancer Institute today report the identification of a novel combination therapy approach to treat pediatric acute myeloid leukemia ...

CERO Therapeutics announces first patient dosed in Phase 1 trial of CER-1236 for acute myeloid leukemia, with upcoming ASCO presentation. CERo Therapeutics Holdings, Inc. has announced the initial ...

In a phase 2 trial of 189 patients with acute schizophrenia, compared with the placebo group, the groups receiving CPL'36 20 or 40 mg once daily both met the primary endpoint of a significant ...

Proteins enriched in intrinsically disordered regions (IDRs) can drive membrane curvature formation in artificial vesicles through liquid-liquid phase separation (LLPS); however, direct evidence ...

28 days to 2 years after the acute phase of infection, reported Yong Chen, PhD, of the University of Pennsylvania in Philadelphia, and colleagues. SARS-CoV-2 infection also was associated with an ...

54. An experimental drug developed by the biotech firm Arvinas and Pfizer — the first in a class of medicines based on a cell’s natural machinery for eliminating diseased proteins — delayed ...

OCS-05 demonstrates safety and efficacy in treating acute optic neuritis, receiving FDA IND clearance for clinical development in the U.S. Small sample size of only 36 patients in the Phase 2 ...

Please provide your email address to receive an email when new articles are posted on . Okogen announced completion of $3.3 million in financing to advance the company through its phase 2b ...

AI protein engineer capable of making proteins 'better, faster, stronger' Date: November 21, 2024 Source: Mass General Brigham Summary: Engineered proteins are critical industrial and medical ...

Upcoming topline results from the ongoing TX45 clinical program includes Phase 1b hemodynamic, proof-of-concept trial data expected in late 1Q or early 2Q’2025, and APEX Phase 2 clinical trial data ...

This was the dose selected for the present phase III studies in which people with moderate to severe acute pain at rest after surgery were randomized 2:2:1 to suzetrigine, hydrocodone bitartrate ...

About Vistagen’s PALISADE Phase 3 Program for Fasedienol for the Acute Treatment of SAD Vistagen's U.S. registration-directed PALISADE Phase 3 development program for fasedienol for the acute ...